Given the fourfold margin between clinical dose and the MTD, no dose reduction of glasdegib was required in the BRIGHT MDS & AML 1003 trial, where patients with AML or high-risk MDS received concomitant CYP3A4 inhibitors [15, 16]. This evidence concerns the gene CYP3A4 and myelodysplastic syndrome.